For gastric carcinoma (GC), aberrant MET activation has been thought to be related to a gene dosage effect [5], and MET gene amplification (GA) or protein overexpression has been associated with aggressive tumor characteristics and/or worse clinical outcome [6]–[14]. This evidence concerns the gene MET and gastric cancer.